Charles Schwab Investment Management Inc. Purchases 27,429 Shares of Inovio Pharmaceuticals, Inc. $INO

Charles Schwab Investment Management Inc. grew its position in shares of Inovio Pharmaceuticals, Inc. (NASDAQ:INO) by 38.6% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 98,495 shares of the biopharmaceutical company’s stock after buying an additional 27,429 shares during the quarter. Charles Schwab Investment Management Inc. owned 0.27% of Inovio Pharmaceuticals worth $161,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Alpine Global Management LLC bought a new position in shares of Inovio Pharmaceuticals during the 4th quarter valued at $31,000. Barclays PLC lifted its holdings in shares of Inovio Pharmaceuticals by 15.0% during the 4th quarter. Barclays PLC now owns 39,114 shares of the biopharmaceutical company’s stock valued at $71,000 after buying an additional 5,111 shares during the period. Jane Street Group LLC lifted its holdings in shares of Inovio Pharmaceuticals by 118.2% during the 4th quarter. Jane Street Group LLC now owns 39,704 shares of the biopharmaceutical company’s stock valued at $73,000 after buying an additional 21,512 shares during the period. Concurrent Investment Advisors LLC bought a new position in shares of Inovio Pharmaceuticals during the 1st quarter valued at $90,000. Finally, Graham Capital Management L.P. bought a new position in shares of Inovio Pharmaceuticals during the 4th quarter valued at $114,000. 26.79% of the stock is owned by institutional investors.

Inovio Pharmaceuticals Stock Performance

Shares of INO stock opened at $2.75 on Friday. Inovio Pharmaceuticals, Inc. has a 52-week low of $1.30 and a 52-week high of $7.00. The firm has a market capitalization of $146.14 million, a PE ratio of -1.05 and a beta of 1.62. The stock has a fifty day simple moving average of $1.72 and a two-hundred day simple moving average of $1.85.

Inovio Pharmaceuticals (NASDAQ:INO) last issued its quarterly earnings results on Tuesday, August 12th. The biopharmaceutical company reported ($0.61) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.63) by $0.02. On average, sell-side analysts forecast that Inovio Pharmaceuticals, Inc. will post -4.23 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on INO shares. Wall Street Zen cut Inovio Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, August 16th. Royal Bank Of Canada restated a “sector perform” rating and issued a $5.00 price objective on shares of Inovio Pharmaceuticals in a research note on Wednesday, May 14th. Oppenheimer reduced their price objective on Inovio Pharmaceuticals from $15.00 to $13.00 and set an “outperform” rating for the company in a research note on Wednesday, May 14th. Piper Sandler started coverage on Inovio Pharmaceuticals in a research note on Wednesday, July 9th. They issued an “overweight” rating and a $5.00 price objective for the company. Finally, HC Wainwright restated a “neutral” rating and issued a $3.00 price objective on shares of Inovio Pharmaceuticals in a research note on Thursday, August 14th. Three investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $8.80.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.